Reducing Hereditary Cancer Act of 2023

Senate Bill 765 - Reducing Hereditary Cancer Act of 2023: Overview, Status, and Impact

Hozzl · 2023-12-15T16:06:31Z

Explore the details of Senate Bill 765 Reducing Hereditary Cancer Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/15/2023, 4:06 PM

Congressional Summary of S 765

Reducing Hereditary Cancer Act of 2023

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 765

Bill S 765 is currently in the status of Bill Introduced since March 9, 2023. Bill S 765 was introduced during Congress 118 and was introduced to the Senate on March 9, 2023. Bill S 765's most recent activity was Read twice and referred to the Committee on Finance. as of March 9, 2023

Bipartisan Support of Bill S 765

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 765

Primary Policy Focus

Health

Potential Impact Areas

- Cancer

- Genetics

- Health care coverage and access

- Health promotion and preventive care

- Hereditary and development disorders

- Medical tests and diagnostic methods

- Medicare

Alternate Title(s) of Bill S 765

Reducing Hereditary Cancer Act of 2023

A bill to amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.